2877 On Other Exchanges
Symbol
Exchange
Hong Kong
OTC US
Stuttgart

china shineway pharmaceutica (2877) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHINA SHINEWAY PHARMACEUTICA (2877)
\

Related News

No related news articles were found.

china shineway pharmaceutica (2877) Related Businessweek News

No Related Businessweek News Found

china shineway pharmaceutica (2877) Details

China Shineway Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and trades in Chinese medicines in the People’s Republic of China. Its principal products include Qing Kai Ling injection, an anti-viral medicine for the treatment of respiratory tract infection, viral hepatitis, cerebral haemorrhage, and cerebral thrombosis; Shu Xie Ning injection for the treatment of cardio-cerebrovascular disease, coronary heart disease, angina pectoris, cerebral embolism, cerebral vasospasm, etc.; and Shen Mai injection for coronary heart disease, viral myocarditis, and pulmonary heart disease. The company also offers Wu Fu Xin Nao Qing soft capsules for the prevention and treatment of coronary heart diseases and cerebral arteriosclerosis; Huo Xiang Zheng Qi soft capsules for the prevention and treatment of heat stroke, stomachache, nausea and diarrhea, and acclimatization sickness; and Pediatric Qing Fei Hua Tan granules for children infected by respiratory tract infections. In addition, it provides Qing Kai Ling soft capsules for the treatment of high fever, viral influenza, and respiratory tract infections; Huamoyan granules for the treatment of acute and chronic synovitis, as well as for after joints surgeries; Dan Deng Tong Nao hard and soft capsules for treatment of stroke caused by congestion, as well as for the treatment and recovery of ischemic infarction; and traditional Chinese medicine formula granules. The company is headquartered in Shijiazhuang, the People’s Republic of China.

3,649 Employees
Last Reported Date: 04/26/19

china shineway pharmaceutica (2877) Top Compensated Officers

Executive Director & CEO
Total Annual Compensation: CNY1.2M
Co-Founder & Executive Chairman
Total Annual Compensation: CNY5.2M
Co-Founder & Executive Director
Total Annual Compensation: CNY3.0M
Executive Director
Total Annual Compensation: CNY2.0M
Executive Director
Total Annual Compensation: CNY1.2M
Compensation as of Fiscal Year 2018.
china shineway pharmaceutica
China Shineway Pharmaceutical Group Limited Recommends Final Ordinary and Special Dividend for the Year Ended December 31, 2018, Payable on 18 June 2019; Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2018

China Shineway Pharmaceutical Group Limited has recommended final ordinary dividend of 12 cents per share and special dividend of 9 cents per share for the year ended December 31, 2018. The dividend will be paid on 18 June 2019, to shareholders of the company whose names appear on the register of members of the company on 11 June 2019. These dividends are subject to approval by the shareholders the forth coming Annual General Meeting. The company reported audited consolidated earnings results for the year ended December 31, 2018. For the year, the company reported turnover of RMB 2,570.196 million against RMB 1,919.608 million a year ago. Profit and total comprehensive income for the year was RMB 505.876 million or 62 cents per basic share against RMB 451.553 million or 55 cents per basic share a year ago.

China Shineway Pharmaceutical Group Limited, Annual General Meeting, May 31, 2019

China Shineway Pharmaceutical Group Limited, Annual General Meeting, May 31, 2019, at 11:00 China Standard Time. Agenda: To receive and consider the audited consolidated financial statements, the report of the directors of the Company and the report of the independent auditor for the year ended 31 December 2018; to re-elect Mr. LI Huimin as Director; to re-elect Mr. CHEN Zhong as Director; to re-elect Ms. CHENG Li as Director; to re-elect Mr. XU Sheng as Director; to re-elect Mr. CHEUNG Chun Yue Anthony as Director; to authorize the board of Directors to fix the remuneration of the Directors; to re-appoint Deloitte Touche Tohmatsu as auditor and to authorize the board of Directors to fix their remuneration; to grant a general mandate to the Directors to repurchase shares of the Company not exceeding 10% of the number of issued shares of the Company; to approve payment of a final dividend of 12 RMB cents (equivalent to HKD 0.1399) per share in respect of the year ended 31 December 2018; and to approve payment of a special dividend.

China Shineway Pharmaceutical Group Limited to Report Fiscal Year 2018 Results on Mar 29, 2019

China Shineway Pharmaceutical Group Limited announced that they will report fiscal year 2018 results on Mar 29, 2019

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

2877 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 2877.
View Industry Companies
 

Industry Analysis

2877

Industry Average

Valuation 2877 Industry Range
Price/Earnings 10.7x
Price/Sales 2.1x
Price/Book 0.9x
Price/Cash Flow 10.8x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CHINA SHINEWAY PHARMACEUTICA, please visit www.shineway.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.